Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne
Launched by STIEFEL, A GSK COMPANY · Dec 10, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit. It is characterized by the formation of comedones, papules, pustules, nodules, cysts, maculae and scars, generally located on the face, chest and back. Acne pathogenesis is recognized as multifactorial.
Acne vulgaris is the most common dermatological disorder. It affects approximately 85% individuals at some point in their lives, generally between 12 and 24 years of age. Although acne is prevalent within this age range, it can persist for many years and its long-term physical and psychological implications can be si...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with mild to moderate acne vulgaris on the face,.
- • Subjects of either sex aged between 12 and 39 years, inclusive.
- • Subjects agreeing not to use sun-beds or undergo any UV light treatment for 4 weeks prior to entering the study and to minimize the amount of exposure to direct sunlight for the duration of the study.
- Exclusion Criteria:
- • Women who are pregnant, breast-feeding, or sexually active with the potential to have children, and not using a contraception method that is safe from a medical point of view
- • Subjects using anti-androgen containing contraceptives.
- • Subjects who, during the past month, have received oral or topical steroids or antibiotics, or acne treatment of any type, including natural or artificial UV therapy.
- • Subjects who have a history of hypersensitivity or idiosyncratic reaction to clindamycin phosphate, benzoyl peroxide, adapalene or any components of the medicinal products which will be used during the study.
- • Subjects using, or having used in the past month, any significant concomitant medicinal product which might affect their acne, as judged by the Investigator.
- • Subjects with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
- • Subjects with a history of photosensitivity.
About Stiefel, A Gsk Company
Stiefel, a GSK Company, is a leading global dermatology-focused organization dedicated to advancing skin health through innovative research and development. With a rich heritage in dermatological solutions, Stiefel leverages GSK's extensive resources and expertise to deliver high-quality products that address a wide range of skin conditions. The company is committed to improving patient outcomes by conducting rigorous clinical trials, fostering collaborations with healthcare professionals, and prioritizing safety and efficacy in its offerings. Through its dedication to science and patient care, Stiefel continues to be at the forefront of dermatological advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Barcelona, , Spain
Badalona, , Spain
Salamanca, , Spain
Pamplona, , Spain
La Coruna, , Spain
Madrid, , Spain
Málaga, , Spain
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials